GAD1 and type 1 diabetes mellitus: This prospective, randomized, control trial of GABA and combined GABA/GAD in children with new-onset T1D confirmed the safety and tolerability of oral GABA, but did not attain its primary objective, the preservation of β-cell function (Fig. 2).